biotech

Altimmune’s $alt has become the talk of Wall Street after the company reported impressive Phase 2b results for its flagship drug, pemvidutide, in the MASH trial. Investors are now closely watching $alt, as the news has driven a surge in trading volumes. With $alt gaining attention from both analysts and individual traders, the stock’s trajectory … Ler mais